Chong Kun Dang Pharmaceutical Corp.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: CKD-501 0.5mgDrug: Placebo
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 173
- Registration Number
- NCT01001611
- Locations
- π°π·
The Hallym University Medical Center, Seoul, Korea, Republic of
π°π·The Korea University Anam Hospital, Seoul, Korea, Republic of
π°π·The Kyung Hee University Medical Center, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath